Preliminary trials have demonstrated a role of IGF-1 intratympanic injections for the treatment of refractory sensorineural hearing loss (although this has not been studied in patients whose hearing loss is related to teprotumumab) (23). This evidence concerns the gene IGF1 and sensorineural hearing loss disorder.